JP2019517549A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517549A5 JP2019517549A5 JP2018564296A JP2018564296A JP2019517549A5 JP 2019517549 A5 JP2019517549 A5 JP 2019517549A5 JP 2018564296 A JP2018564296 A JP 2018564296A JP 2018564296 A JP2018564296 A JP 2018564296A JP 2019517549 A5 JP2019517549 A5 JP 2019517549A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- chain variable
- variable domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662348720P | 2016-06-10 | 2016-06-10 | |
| US62/348,720 | 2016-06-10 | ||
| PCT/IB2017/053405 WO2017212442A1 (en) | 2016-06-10 | 2017-06-08 | Therapeutic uses of a c-raf inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019517549A JP2019517549A (ja) | 2019-06-24 |
| JP2019517549A5 true JP2019517549A5 (enExample) | 2020-07-16 |
Family
ID=59215827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018564296A Pending JP2019517549A (ja) | 2016-06-10 | 2017-06-08 | Ｃ−ｒａｆ阻害薬の治療的使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190175609A1 (enExample) |
| EP (1) | EP3468595A1 (enExample) |
| JP (1) | JP2019517549A (enExample) |
| KR (1) | KR20190017767A (enExample) |
| CN (1) | CN109310761A (enExample) |
| AU (1) | AU2017279046B2 (enExample) |
| BR (1) | BR112018075371A2 (enExample) |
| CA (1) | CA3026876A1 (enExample) |
| CL (1) | CL2018003530A1 (enExample) |
| IL (1) | IL262961A (enExample) |
| MX (1) | MX2018015353A (enExample) |
| RU (1) | RU2018146886A (enExample) |
| WO (1) | WO2017212442A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018051306A1 (en) * | 2016-09-19 | 2018-03-22 | Novartis Ag | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor |
| KR20240032157A (ko) | 2017-05-02 | 2024-03-08 | 노파르티스 아게 | 병용 요법 |
| WO2020185516A1 (en) | 2019-03-08 | 2020-09-17 | Auris Health, Inc. | Tilt mechanisms for medical systems and applications tilt mechanisms for medical systems and applications tilt mechanisms for medical systems and applications tilt mechanisms for medical systems and applications tilt mechanisms for medical systems and |
| MX2021013817A (es) | 2019-05-13 | 2021-12-14 | Novartis Ag | Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer. |
| EP4048259A4 (en) | 2019-10-24 | 2023-08-02 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| WO2021110141A1 (zh) * | 2019-12-06 | 2021-06-10 | 南京明德新药研发有限公司 | Pan-RAF激酶抑制剂的联芳基化合物 |
| CN113912591B (zh) * | 2020-07-08 | 2023-10-20 | 齐鲁制药有限公司 | 联芳基化合物 |
| CN117425650A (zh) * | 2021-06-04 | 2024-01-19 | 齐鲁制药有限公司 | 一种raf激酶抑制剂的晶型及其制备方法 |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR090151A1 (es) * | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| ES2716685T3 (es) | 2014-01-24 | 2019-06-14 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo para PD-1 y usos de las mismas |
| WO2015119930A1 (en) * | 2014-02-04 | 2015-08-13 | Pfizer Inc. | Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer |
| EP3563870A1 (en) * | 2014-07-15 | 2019-11-06 | F. Hoffmann-La Roche AG | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
-
2017
- 2017-06-08 RU RU2018146886A patent/RU2018146886A/ru not_active Application Discontinuation
- 2017-06-08 BR BR112018075371-8A patent/BR112018075371A2/pt not_active Application Discontinuation
- 2017-06-08 US US16/307,920 patent/US20190175609A1/en not_active Abandoned
- 2017-06-08 WO PCT/IB2017/053405 patent/WO2017212442A1/en not_active Ceased
- 2017-06-08 AU AU2017279046A patent/AU2017279046B2/en not_active Ceased
- 2017-06-08 EP EP17733028.9A patent/EP3468595A1/en not_active Withdrawn
- 2017-06-08 KR KR1020187035219A patent/KR20190017767A/ko not_active Ceased
- 2017-06-08 CN CN201780035192.1A patent/CN109310761A/zh active Pending
- 2017-06-08 CA CA3026876A patent/CA3026876A1/en not_active Abandoned
- 2017-06-08 MX MX2018015353A patent/MX2018015353A/es unknown
- 2017-06-08 JP JP2018564296A patent/JP2019517549A/ja active Pending
-
2018
- 2018-11-12 IL IL262961A patent/IL262961A/en unknown
- 2018-12-07 CL CL2018003530A patent/CL2018003530A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517549A5 (enExample) | ||
| TWI764943B (zh) | 一種抗pd-1抗體和vegfr抑制劑聯合在製備治療癌症的藥物中的用途 | |
| RU2018146886A (ru) | Пути терапевтического применения ингибитора c-raf | |
| JP6141958B2 (ja) | 増殖性疾患の治療のための併用療法（ベムラフェニブ及びｍｄｍ２阻害剤） | |
| CA2856646C (en) | Combination treatment of cancer | |
| TW201922793A (zh) | Ｐｄ－１抗體和ｖｅｇｆｒ抑制劑聯合治療小細胞肺癌的用途 | |
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| CN111132696B (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| CN106414493A (zh) | 包含突变的ras肽和化疗剂的肽疫苗 | |
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| JP2014513705A (ja) | 進行性固形腫瘍の治療方法 | |
| JP2023542093A (ja) | 抗腫瘍治療におけるチアウラニブと免疫チェックポイント阻害剤との組み合わせの使用 | |
| JP2015500822A5 (enExample) | ||
| TW201914592A (zh) | 阿帕替尼和c-Met抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| CN104203232A (zh) | 用于抗肿瘤试剂施用的方法 | |
| CN102438608A (zh) | 包含ave8062和索拉非尼的抗肿瘤组合 | |
| WO2020233602A1 (zh) | 用于联合治疗小细胞肺癌的喹啉衍生物 | |
| TW200306185A (en) | Combinations comprising EPOTHILONES and anti-metabolites | |
| US20200237779A1 (en) | Combination therapy with a bet inhibitor and a bcl-2 inhibitor | |
| CN101346137A (zh) | 含有孔布勒塔斯塔坦与抗癌剂的组合物 | |
| WO2023174408A1 (zh) | 抗tim-3抗体与抗pd-l1抗体的药物组合 | |
| JP6549107B2 (ja) | がんの処置のための、ｒｏ５５０３７８１、カペシタビン及びオキサリプラチンの組み合わせ | |
| TW201306833A (zh) | 包含康布列塔司他汀（ｃｏｍｂｒｅｔａｓｔａｔｉｎｓ）族衍生物及西妥昔單抗（ｃｅｔｕｘｉｍａｂ）之組合 | |
| AU2015242786A1 (en) | Anti-tumor agent containing anti-tumor platinum complex, and anti-tumor effect enhancer | |
| JP2022526525A (ja) | 癌療法のためのイアダデムスタット（ｉａｄａｄｅｍｓｔａｔ）の組み合わせ物 |